Icosavax Inc (DELISTED) (ICVX:DL)
15.31
0.00 (0.00%)
USD |
NASDAQ |
Feb 29, 16:00
Icosavax SG&A Expense (Quarterly): 8.607M for Sept. 30, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 8.607M |
| June 30, 2023 | 9.129M |
| March 31, 2023 | 9.165M |
| December 31, 2022 | 8.938M |
| September 30, 2022 | 7.659M |
| June 30, 2022 | 7.311M |
| March 31, 2022 | 6.322M |
| December 31, 2021 | 6.218M |
| Date | Value |
|---|---|
| September 30, 2021 | 25.36M |
| June 30, 2021 | 2.221M |
| March 31, 2021 | 1.091M |
| December 31, 2020 | 0.802M |
| September 30, 2020 | 0.704M |
| June 30, 2020 | 0.541M |
| March 31, 2020 | 0.612M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.541M
Minimum
Jun 2020
25.36M
Maximum
Sep 2021
6.312M
Average
6.322M
Median
Mar 2022
SG&A Expense (Quarterly) Benchmarks
| Karuna Therapeutics Inc (DELISTED) | 47.39M |
| Immunogen Inc (DELISTED) | 37.74M |
| AbbVie Inc | 3.315B |
| Assure Holdings Corp | 3.419M |
| Harpoon Therapeutics Inc (DELISTED) | 4.262M |